Mopride Tablet 2 mg

Mopride is a prescription medication containing Prucalopride Succinate (2 mg) formulated as tablets. Manufactured by Beximco Pharmaceuticals Ltd, it treats chronic constipation in adults unresponsive to laxatives. Priced at ৳24.00 per unit, the strip costs ৳360.00 for 15 tablets.

This osmotic purgative selectively activates 5-HT4 receptors in gastrointestinal smooth muscles, enhancing acetylcholine release to stimulate colonic motility. Unlike similar drugs, it minimizes cardiovascular risks by avoiding hERG channel interactions.

Dosage Guidelines:

• Adults: 2 mg once daily, before/after meals
• Elderly: Start with 1 mg, may increase to 2 mg
• Children: Not recommended below 18 years

Avoid exceeding 2 mg/day. Store below 30°C in original containers with desiccants.

Drug interactions are limited but significant with CYP3A4/P-gp inhibitors like ketoconazole, increasing prucalopride levels by 40%. No notable interactions exist with warfarin, digoxin, or alcohol.

Side Effects: Headache, abdominal pain, nausea, and diarrhea are common but often resolve spontaneously. Severe electrolyte imbalance from overdose requires symptomatic treatment.

Contraindicated in pregnancy/lactation. Women of childbearing potential must use contraception. Explore alternatives like other osmotic purgatives after consulting physicians.

Adults: 2 mg once daily (pre/post-meal). Elderly: Start with 1 mg, may increase to 2 mg. Renal impairment (GFR <30): 1 mg daily. Hepatic impairment: Initiate with 1 mg. Re-evaluate if no effect after 2 weeks.

The most frequently reported adverse reactions associated with Mopride therapy are headache (17.8%) and gastrointestinal symptoms (abdominal pain), nausea and diarrhoea. The adverse reactions occur predominantly at the start of therapy and usually disappear within a few days with continued treatment. Other adverse reactions have been reported occasionally. The majority of adverse events were mild to moderate in intensity.

Pregnancy Category C – contraindicated. Avoid during breastfeeding. Contraception required. Animal studies show no risk but human safety unconfirmed.

Contains lactose – avoid in galactose intolerance. Monitor electrolytes during diarrhea. Track bowel movement patterns for efficacy assessment.

Pediatrics: Not for <18 years. Geriatrics: Start with reduced dose. Renal: 1 mg/day if GFR <30. Hepatic: Initiate 1 mg in Child-Pugh C.

An overdose may result in symptoms resulting from an exaggeration of prucalopride’s known pharmacodynamic effects and include headache, nausea and diarrhoea. Specific treatment is not available for Mopride overdose. Should an overdose occur, the patient should be treated symptomatically and supportive measures instituted, as required. Extensive fluid loss by diarrhoea or vomiting may require correction of electrolyte disturbances.